Inventor · disambiguated record
Hexiang Wang
Also filed as: WANG HEXIANG
14 granted patents·10 pending applications·159 citations·filing 2011–2024
91Inventor score
Files withBEIGENE LTD18BEIGENE SWITZERLAND GMBH3ZHOU CHANGYOU2PYROTECH BEIJING BIOTECHNOLOGY CO LTD1
Top patents by PatentIndex Score
24 records- 0195US9328111B2Substituted cycloocta[5,6]pyrido[4,3,2-de]phthalazines as PARP inhibitorsZHOU CHANGYOU·Filed 2011·Granted May 3, 2016·102 cites·6 claims
- 0292US11202782B2Treatment cancers using a combination comprising PARP inhibitorsBEIGENE LTD·Filed 2017·Granted Dec 21, 2021·9 cites·29 claims
- 0392US10112952B2Fused tetra or penta-cyclic dihydrodiazepinocarbazolones as PARP inhibitorsBEIGENE LTD·Filed 2017·Granted Oct 30, 2018·5 cites·17 claims
- 0490US9393232B2Substituted 5-(3,5-dimethylisoxazol-4-yl)indoline-2-onesBEIGENE LTD·Filed 2014·Granted Jul 19, 2016·15 cites·12 claims
- 0587US10501467B2Fused tetra or penta-cyclic dihydrodiazepinocarbazolones as PARP inhibitorsBEIGENE LTD·Filed 2018·Granted Dec 10, 2019·2 cites·17 claims
- 0687US9617273B2Fused tetra or penta-cyclic dihydrodiazepinocarbazolones as PARP inhibitorsBEIGENE LTD·Filed 2016·Granted Apr 11, 2017·6 cites·10 claims
- 0785US10280163B25 or 8-substituted imidazo[1, 5-a] pyridines as indoleamine and/or tryptophane 2, 3-dioxygenasesBEIGENE LTD·Filed 2016·Granted May 7, 2019·5 cites·30 claims
- 0883US9260440B2Fused tetra or penta-cyclic dihydrodiazepinocarbazolones as PARP inhibitorsZHOU CHANGYOU·Filed 2011·Granted Feb 16, 2016·7 cites·6 claims
- 0980US10457680B2Process for preparing a PARP inhibitor, crystalline forms, and uses thereofBEIGENE LTD·Filed 2016·Granted Oct 29, 2019·3 cites·23 claims
- 1079US10899763B2Crystalline forms of salts of fused penta-cyclic dihydrodiazepinocarbazolones, and uses thereofBEIGENE LTD·Filed 2018·Granted Jan 26, 2021·1 cites·26 claims
- 1179US10647714B25 or 8-substituted imidazo[1,5-a]pyridines as indoleamine and/or tryptophane 2,3-dioxygenasesBEIGENE LTD·Filed 2019·Granted May 12, 2020·2 cites·29 claims
- 1277US11472788B2Benzoimidazoles as selective inhibitors of indoleamine 2,3-dioxygenasesBEIGENE LTD·Filed 2018·Granted Oct 18, 2022·1 cites·7 claims
- 1373US10882856B25 or 8-substituted imidazo [1,5-a] pyridines as selective inhibitors of indoleamine and/or tryptophane 2,3-dioxygenasesBEIGENE LTD·Filed 2017·Granted Jan 5, 2021·1 cites·33 claims
- 1468US2024366769A1Degradation of bruton's tyrosine kinase (btk) by conjugation of btk inhibitors with e3 ligase ligand and methods of useBEIGENE SWITZERLAND GMBH·Filed 2024·Application pending·0 cites
- 1563US2024366770A1Degradation of bruton's tyrosine kinase (btk) by conjugation of btk inhibitors with e3 ligase ligand and methods of useBEIGENE SWITZERLAND GMBH·Filed 2024·Application pending·0 cites
- 1654US2025034197A1Nucleoside-diphosphate-heptose compounds for treating conditions associated with alpk1 activityPYROTECH BEIJING BIOTECHNOLOGY CO LTD·Filed 2022·Application pending·0 cites
- 1753US2024246977A1Degradation of bruton's tyrosine kinase (btk) by conjugation of btk inhibitors with e3 ligase ligand and method of useBEIGENE SWITZERLAND GMBH·Filed 2021·Application pending·0 cites
- 1851US2023167118A1Degradation of bruton's tyrosine kinase (btk) by conjugation of btk inidbitors with e3 ligase ligand and methods of useBEIGENE LTD·Filed 2021·Application pending·0 cites
- 1950US2023322761A1Degradation of bruton's tyrosine kinase (btk) by conjugation of btk inhibitors with e3 ligase ligand and methods of useBEIGENE LTD·Filed 2021·Application pending·0 cites
- 2050US2022227762A1Amide-substituted imidazo compounds as selective inhibitors of indoleamine 2,3-dioxygenasesBEIGENE LTD·Filed 2020·Application pending·0 cites
- 2147US2020155567A1Treatment of cancers using a combination comprising parp inhibitors, temozolomide and/or radiation therapyBEIGENE LTD·Filed 2018·Application pending·0 cites
- 2246US9827226B2Substituted 5-(3,5-dimethylisoxazol-4-yl)indoline-2-onesBEIGENE LTD·Filed 2016·Granted Nov 28, 2017·0 cites·11 claims
- 2345US2022281876A1Degradation of bruton's tyrosine kinase (btk) by conjugation of btk inhibitors with e3 ligase ligand and methods of useBEIGENE LTD·Filed 2020·Application pending·0 cites
- 2441US2021205323A1Maintenance therapy of a parp inhibitor in treating gastric cancerBEIGENE LTD·Filed 2019·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Hexiang Wang files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →